Multiple published studies have demonstrated that the level of ST2 in blood can help a physician better predict a patient's prognosis, and thus make better treatment decisions than solely employing clinical parameters and existing laboratory assays.

While BNP and NT-proBNP may help a physician diagnose heart failure in a symptomatic patient, ST2 is most useful in determining the patient's likely prognosis, regardless of their symptom status. Furthermore, ST2 enhances prognosis when used in conjunction with peptide markers.

In short, ST2 provides new insight on cardiovascular disease progression - relevant clinical information that other biomarkers miss.